About us

About Us | GlycoBioSciences Inc.

GlycoBioSciences Inc. is a pharmaceutical company exclusively devoted to the sale, licensing and development of therapeutic products based on our Ionic Polymer Matrix (IPMTM) technology. Our IPM Wound Gel Bio product is FDA cleared under 510 (k)s K123193 and K143527. Glyco has patents applications pending in the US, Canada and the EU as well as several other countires that covers Glyco IPM Wound Gel Bio product and Ionic Polymer Matrix technology. Glyco currently has license partners in Hong Kong, Macua and Mexico, and is working on distribution agreements in several other countries. Glyco anticiaptes having supply of our IPM Wound Gel Bio product ready at the beginning of Q2 2017, and to launch the product in several markets including the US.